Amanda is a senior reporter with more than 20 years' experience as a writer and editor. She has previously been a staff writer for The West Australian and a journalist for The Sunday Times, the Kalgoorlie Miner, Australia’s Mining Monthly and ResourceStocks. While living in the UK, Amanda wrote for the Newsquest group. She has also written for a broad variety of Australian online news outlets and was a publications manager for the Western Australian government. Amanda has a master’s degree in international journalism from the University of Western Australia, an undergraduate degree in commerce, and a diploma in journalism from the British National Council for the Training of Journalists. She has strong interests in history and book publishing.
If Bronchitol is approved later this year, Pharmaxis is down to receive US$10 million.
The oncology-focused biotech is a mid-clinical-stage therapeutics company.
THC is executing a medicinal cannabis strategy in Australia, New Zealand and Canada and is looking to Asian markets.
The company hopes to improve its share price with ADAPT technology successes.
The deal is part of a concerted effort by the company to “unlock shareholder value” with strategic deals that open up new markets.
The investor event starts at 3pm on the main drag of the trendy Perth suburb of Mt Lawley.
The biotechnology company is focused on its R&D program and is funded with a $1.9 million R&D loan from Paddington Street Finance Pty Ltd.
The research note puts the value per share at 14 cents each, or 12 cents after dilutions.